AstraZeneca’s Imfinzi breaks decade Long Drought in Cholangiocarcinoma By Steve|2023-12-09T09:44:46+13:00December 5th, 2023|All, IMMUNOTHERAPY| Read More 0
Transforming Cancer Perceptions: The Power of Objectivity By Steve|2023-12-04T15:49:29+13:00December 4th, 2023|All| Read More 0
Exploring HIPEC Surgery: A Potential Ally in Abdominal Cancer Battles By Steve|2023-11-24T15:50:57+13:00November 24th, 2023|All, Education| Read More 0
Clarifying: What is the Checkpoint Pathway? By Steve|2023-11-25T19:17:04+13:00November 20th, 2023|All, Education| Read More 0
The Battle for the Checkpoint Pathway By Steve|2023-11-20T20:15:50+13:00November 20th, 2023|All, Education| Read More 0
The Basics difference between Gem/Cis with Durvalumab vs. Keytruda By Steve|2023-11-22T10:42:31+13:00November 18th, 2023|All, Updates| Read More 0
Merck’s Keytruda: A New Hope in Biliary Tract Cancer By Steve|2023-11-05T17:08:56+13:00November 5th, 2023|All| Read More 0
PBAC Recommends IMFINZI (durvalumab) for Cholangiocarcinoma Patients in Australia By Steve|2023-08-30T16:28:25+12:00August 29th, 2023|All, Media, Updates| Read More 0
Steven West: Cholangio Survivor By Steve|2023-09-01T13:53:34+12:00August 2nd, 2023|All, Testimonials| Read More 0
Karen O’Hagan-Humphries: Cholangio Survivor By Steve|2023-08-04T13:05:09+12:00August 2nd, 2023|All, Testimonials| Read More 0
Lynette Williams: Cholangio Survivor By Steve|2023-09-01T13:56:58+12:00July 31st, 2023|All, Testimonials| Read More 0
Lisa Salem-Craine: Cholangio Survivor By Steve|2023-09-01T13:57:10+12:00July 25th, 2023|All, Testimonials| Read More 0